Physician profile
Robin Beavers
NPI 1730797622
$3,246.62
in general payments reported to CMS, 2019-2025
26 companies · $1,804 in 2025
The $1,804 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $194 · 2022: $346 · 2023: $254 · 2024: $649 · 2025: $1,804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,919 · Travel and Lodging: $788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,919.48 |
| Travel and Lodging | $787.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,597.63 | 2023-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Forte Bio-Pharma LLC | $266.18 | 2022-2024 | Prolate, Nalocet |
| Saluda Medical Americas, INC. | $218.37 | 2024-2025 | Evoke |
| Collegium Pharmaceutical, INC. | $216.04 | 2021-2024 | Xtampza, Belbuca |
| Nevro Corp. | $143.39 | 2024 | Senza |
| Medtronic, INC. | $139.48 | 2022 | |
| Globus Medical, INC. | $106.91 | 2025 | Senza |
| Vertos Medical, INC. | $59.87 | 2024 | Mild Device Kit |
| Biotronik Nro, INC. | $56.83 | 2023-2024 | Biotronik, Prospera |
| Tersera Therapeutics LLC | $56.47 | 2022-2024 | Prialt |
| Nalu Medical, INC. | $52.05 | 2021-2025 | Nalu Neurostimulation System |
| Relievant Medsystems, INC. | $41.22 | 2022 | |
| Eisai INC. | $36.60 | 2021 | |
| Amgen INC. | $34.29 | 2021 | |
| Scilex Pharmaceuticals INC. | $31.74 | 2022-2023 | Ztlido |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.05 | 2025 | Relistor |
| Grt US Holding, INC. | $21.46 | 2022 | |
| Averitas Pharma INC. | $20.97 | 2023 | Qutenza |
| Vertex Pharmaceuticals Incorporated | $20.48 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.39 | 2022 | |
| Redhill Biopharma INC. | $17.08 | 2021 | |
| Pfizer INC. | $16.04 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $14.17 | 2021 | |
| Protega Pharmaceutials INC | $13.27 | 2023 | Roxybond |
| Curonix LLC | $12.95 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Acelrx Pharmaceuticals, INC. | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Beavers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.